If you have been reading about Gastric juice protein and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-06-05. Numbers and descriptions here follow the published literature rather than marketing material.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Purity is ordinarily reported as a percentage from reverse-phase high-performance liquid chromatography, where the area of the main peak is compared with the total peak area. Identity is confirmed by mass spectrometry, since the measured mass can be checked against the value calculated from the sequence. Some certificates also include amino acid analysis or sequence confirmation by tandem mass spectrometry. A single purity number does not describe the profile of related impurities, so the underlying chromatogram and spectrum usually carry more information than the headline figure.
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentadecapeptide | Fifteen amino acids; sequence matches a fragment of a gastric juice protein |
| Molecular formula | C62H98N16O22 | Corresponds to a molecular mass near 1419 Da |
| Primary origin | Fragment of human gastric juice protein BPC | First characterized in the early 1990s |
| Common synonyms | BPC 157; PL 14736; pentadecapeptide BPC 157 | Naming conventions vary across publications |
| Reported stability | Stable in gastric juice during in vitro incubation | Based on laboratory incubation, not clinical data |
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
Lyophilized material is generally kept cold, commonly at minus twenty degrees Celsius, and shielded from moisture and light. Solutions are less stable than the dry powder, so repeated freeze-thaw cycles are avoided by splitting the material into single-use portions. Published stability data for this particular peptide are limited, which means suggested hold times should be read as provisional. Long-term refrigeration of reconstituted solutions is not well supported by available evidence.
Identity and purity are checked with standard peptide techniques. Reversed-phase high-performance liquid chromatography separates the main peak from closely related impurities and yields a percentage purity. Mass spectrometry confirms that the measured mass matches the theoretical value. Amino acid analysis offers an independent check on overall composition. These analytical methods characterize the material itself and reveal nothing about how it behaves in a living system.
In its common research form the peptide is supplied as a lyophilized powder. It dissolves readily in water and in typical aqueous buffers, which simplifies preparation of working solutions. Laboratories usually prepare small aliquots instead of one large volume. The dry material appears as a white to off-white solid with no distinctive odor. Bulk quantities are typically shipped in sealed vials.
Thus, the BLT1 receptor exhibits exquisite specificity, binding 5(S),12(R)-dihydroxy-6Z,8E,10E,14Z-eicosatetraenoic acid (i.e. LTB4) but not LTB4's 12(S) or 6Z isomers while the BLT2 receptor exhibits a promiscuous finding pattern. Formyl peptide receptor 2 is a relevant and well-studied example of promiscuous receptors. Initially thought to be a second and low affinity receptor for the neutrophil tripeptide chemotactic factor, N-formyl-met-leu-phe, subsequent studies showed that it was a high affinity receptor for the arachidonic acid metabolite, lipoxin A4, but also bound and was activated by a wide range of peptides, proteins, and other agents. BLT2 may ultimately prove to have binding specificity for a similarly broad range of agents. The production of LTB4 and expression of BLT1 by human tissues are largely limited to bone marrow-derived cells such as the neutrophil, eosinophil, mast cell, and various types of lymphocytes and accordingly are regarded primarily as contributing to the many human defensive and pathological (ulcerative colitis, arthritis, asthma, etc.) inflammatory responses which are mediated by these cell types. Drugs that inhibit LTB4 production or binding to BLT1 are in use or development for the latter diseases. In contrast, the production of 12-HHT and expression of BLT2 receptors by human tissues is far wider and more robust than that of the LTB4/BLT2 receptor axis. Recent studies indicate that the role(s) of the 12-HHT/BLT2 receptor axis in human physiology and pathology may be very different from those of the LTB4/BLT1 axis.
=== Creation === Smashburger was founded in 2007 by two fast food industry veterans. Tom Ryan had previously helped to develop the stuffed crust pizza concept for Pizza Hut and later served as chief concept officer for McDonald's, and Rich Schaden was a former owner of Quiznos. The two launched the venture with private equity firm Consumer Capital Partners. The restaurant was envisioned to highlight a higher market for hamburgers, as a part of a wave of "better burger" restaurants including Shake Shack, which uses similar techniques. It adopted the name Smashburger, Ryan later said, because the name "had this really great hand-crafted connotation, which we do. It also kind of had this organic, earthy, commonly popular approach, and it had a little edginess to it, for younger [generation] people." Ryan has a Ph.D. in flavor and fragrance technology and lipid toxicology from Michigan State University. With $15 million in capital, the two bought a Denver restaurant, Icon Burger, to experiment with cooking and management techniques for a higher-end burger restaurant. The founders then spent six months developing an efficient and fast "kitchen engine", designing the restaurant's kitchen to have modular surfaces, and with a central griddle that houses a refrigerated area underneath where meatballs are stored. This allows the burger cook to be properly supplied without having to walk away from the griddle. The kitchen concept was later adapted and standardized for every Smashburger location.
== Safety == Possible hazards include implosions resulting from use of glassware that contains flaws, such as star-cracks. Explosions may occur from concentrating unstable impurities during evaporation, for example when rotavapping an ethereal solution containing peroxides. This can also occur when taking certain unstable compounds, such as organic azides and acetylides, nitro-containing compounds, molecules with strain energy, etc. to dryness. Users of rotary evaporation equipment must take precautions to avoid contact with rotating parts, particularly entanglement of loose clothing, hair, or necklaces. Under these circumstances, the winding action of the rotating parts can draw the users into the apparatus resulting in breakage of glassware, burns, and chemical exposure. Extra caution must also be applied to operations with air reactive materials, especially when under vacuum. A leak can draw air into the apparatus and a violent reaction can occur.
==== MeSH D13.695.827 – ribonucleotides ==== MeSH D13.695.827.068 – adenine nucleotides MeSH D13.695.827.068.124 – adenosine diphosphate MeSH D13.695.827.068.124.070 – adenosine diphosphate sugars MeSH D13.695.827.068.124.070.075 – adenosine diphosphate glucose MeSH D13.695.827.068.124.070.125 – adenosine diphosphate ribose MeSH D13.695.827.068.124.070.125.040 – o-acetyl-adp-ribose MeSH D13.695.827.068.124.070.125.195 – cyclic adp-ribose MeSH D13.695.827.068.180 – adenosine monophosphate MeSH D13.695.827.068.180.080 – adenosine phosphosulfate MeSH D13.695.827.068.236 – adenosine triphosphate MeSH D13.695.827.068.236.050 – adenylyl imidodiphosphate MeSH D13.695.827.068.236.250 – ethenoadenosine triphosphate MeSH D13.695.827.068.382 – coenzyme a MeSH D13.695.827.068.382.300 – acyl coenzyme a MeSH D13.695.827.068.382.300.020 – acetyl coenzyme a MeSH D13.695.827.068.382.300.500 – malonyl coenzyme a MeSH D13.695.827.068.382.300.700 – palmitoyl coenzyme a MeSH D13.695.827.068.395 – cyclic amp MeSH D13.695.827.068.395.225 – 8-bromo cyclic adenosine monophosphate MeSH D13.695.827.068.395.250 – bucladesine MeSH D13.695.827.068.506 – flavin-adenine dinucleotide MeSH D13.695.827.068.694 – nad MeSH D13.695.827.068.749 – nadp MeSH D13.695.827.068.850 – phosphoadenosine phosphosulfate MeSH D13.695.827.232 – cytosine nucleotides MeSH D13.695.827.232.115 – cyclic cmp MeSH D13.695.827.232.150 – cytidine diphosphate MeSH D13.695.827.232.150.180 – cytidine diphosphate choline MeSH D13.695.827.232.150.210 – cytidine diphosphate diglycerides MeSH D13.695.827.232.370 – cytidine monophosphate MeSH D13.695.827.232.370.250 – cytidine monophosphate n-acetylneuraminic acid MeSH D13.695.827.232.400 – cytidine triphosphate MeSH D13.695.827.349 – flavin mononucleotide MeSH D13.695.827.426 – guanine nucleotides MeSH D13.695.827.426.160 – cyclic gmp MeSH D13.695.827.426.160.325 – dibutyryl cyclic gmp MeSH D13.695.827.426.340 – guanosine diphosphate MeSH D13.695.827.426.340.350 – guanosine diphosphate sugars MeSH D13.695.827.426.340.350.400 – guanosine diphosphate fucose MeSH D13.695.827.426.340.350.500 – guanosine diphosphate mannose MeSH D13.695.827.426.440 – guanosine pentaphosphate MeSH D13.695.827.426.480 – guanosine tetraphosphate MeSH D13.695.827.426.504 – guanosine triphosphate MeSH D13.695.827.426.504.380 – guanosine 5'-o-(3-thiotriphosphate) MeSH D13.695.827.426.504.400 – guanylyl imidodiphosphate MeSH D13.695.827.426.525 – 5'-guanylic acid MeSH D13.695.827.426.700 – rna caps MeSH D13.695.827.426.700.710 – rna cap analogs MeSH D13.695.827.519 – inosine nucleotides MeSH D13.695.827.519.300 – cyclic imp MeSH D13.695.827.519.400 – inosine diphosphate MeSH D13.695.827.519.500 – inosine monophosphate MeSH D13.695.827.519.800 – inosine triphosphate MeSH D13.695.827.648 – nicotinamide mononucleotide MeSH D13.695.827.708 – nucleoside diphosphate sugars MeSH D13.695.827.708.070 – adenosine diphosphate sugars MeSH D13.695.827.708.070.075 – adenosine diphosphate glucose MeSH D13.695.827.708.070.125 – adenosine diphosphate ribose MeSH D13.695.827.708.070.125.040 – o-acetyl-adp-ribose MeSH D13.695.827.708.070.125.195 – cyclic adp-ribose MeSH D13.695.827.708.070.125.600 – poly adenosine diphosphate ribose MeSH D13.695.827.708.260 – cytidine diphosphate diglycerides MeSH D13.695.827.708.400 – guanosine diphosphate sugars MeSH D13.695.827.708.400.410 – guanosine diphosphate fucose MeSH D13.695.827.708.400.500 – guanosine diphosphate mannose MeSH D13.695.827.708.727 – uridine diphosphate sugars MeSH D13.695.827.708.727.100 – uridine diphosphate n-acetylgalactosamine MeSH D13.695.827.708.727.120 – uridine diphosphate n-acetylglucosamine MeSH D13.695.827.708.727.150 – uridine diphosphate n-acetylmuramic acid MeSH D13.695.827.708.727.300 – uridine diphosphate galactose MeSH D13.695.827.708.727.350 – uridine diphosphate glucose MeSH D13.695.827.708.727.375 – uridine diphosphate glucuronic acid MeSH D13.695.827.708.727.800 – uridine diphosphate xylose MeSH D13.695.827.919 – uracil nucleotides MeSH D13.695.827.919.600 – uridine diphosphate MeSH D13.695.827.919.600.677 – uridine diphosphate sugars MeSH D13.695.827.919.600.677.100 – uridine diphosphate n-acetylgalactosamine MeSH D13.695.827.919.600.677.120 – uridine diphosphate n-acetylglucosamine MeSH D13.695.827.919.600.677.150 – uridine diphosphate n-acetylmuramic acid MeSH D13.695.827.919.600.677.300 – uridine diphosphate galactose MeSH D13.695.827.919.600.677.350 – uridine diphosphate glucose MeSH D13.695.827.919.600.677.375 – uridine diphosphate glucuronic acid MeSH D13.695.827.919.600.677.800 – uridine diphosphate xylose MeSH D13.695.827.919.877 – uridine monophosphate MeSH D13.695.827.919.950 – uridine triphosphate
Sources: en.wikipedia.org
LEDs have many advantages over incandescent light sources, including lower power consumption, reduced waste heat, a longer lifetime, improved physical robustness, smaller sizes, and faster switching. In exchange for these generally favorable attributes, disadvantages of LEDs include electrical limitations to low voltage and generally to DC (not AC) power, the inability to provide steady illumination from a pulsing DC or an AC electrical supply source, and a lesser maximum operating temperature and storage temperature. LEDs are transducers of electricity into light.
==== Companion of the Order of the Bath (CB) ==== Military Rear Admiral Andrew Betton, , Royal Navy, C033663C. Rear Admiral James David Morley, Royal Navy, C034410Y Major General Kevin Mark Copsey, , 533047. Major General John Robert Mead, , 537468. Air Vice-Marshal Nigel James Colman, , Royal Air Force, 8304546T. Air Marshal Ian David Gale, , Royal Air Force, 8304212Q. Civil Ruth Léonie Hannant, Director General, Policy, Department for Culture, Media and Sport. For Public Service. Liam Cledwyn Laurence Smyth, Clerk of Legislation, House of Commons. For services to Parliament. Jonathan Marron, Director General, Office of Health Inequalities and Disparities, Department of Health and Social Care. For services to Public Health. Lee McDonough, Director General, Net Zero, Nuclear and International, Department for Energy Security and Net Zero. For services to Energy and Climate. Simon Millhouse, Ministry of Defence. For services to Defence. Neil Brendan O'Connor, , lately Director, Building Safety Programme, Department for Levelling Up, Housing and Communities. For services to Building Safety. Polly Theresa Payne, Director General, Policy, Department for Culture, Media and Sport. For Public Service. Sir Arthur Gareth Ludovic Emrys Rhys Williams, , Government Chief Commercial Officer, Cabinet Office. For Public Service. Kenneth Andrew Lyons Thomson, lately Director General, Scottish Government. For Public Service. Brendan Peter Threlfall, , Director General, Union and Windsor Framework, Cabinet Office. For Public Service. Dr Abigail Tierney, lately Director General, Home Office.
Additionally, CAM providers are concerned by the closure of other CAM laboratories under CLIA, and have sought to avoid detection. Some CAM providers and laboratory personnel have not had exposure to laboratory curriculum and are unaware of CLIA requirements. CLIA is largely reliant on laboratories to self-identify themselves for enrollment. Providers of CAM laboratories have opposed CLIA oversight and suggested they be regulated by their peers or by a CAM-specific division. CAM providers have stated that they should be exempt from CLIA since CAM laboratories do not participate in health insurance. Others claim that they are exempt from CLIA because the tests are performed solely for research purposes and not used in patient care and treatment decisions. Several pathologists have stated that CAM testing falls within the scope of their medical license and should not be regulated under CLIA. CLIA provisions are geared towards CLIA-certified laboratories, but not for those that have not enrolled. When a CAM laboratory is found to be operating without a CLIA certificate, they are sent a cease and desist letter to stop testing until the laboratory is CLIA certified. There are no administrative remedies available to CMS when a laboratory refuses to enroll in CLIA and refuses to cease testing. CMS cannot impose monetary or other administrative penalties on laboratories that defy the law, but can only refer cases to other Federal or State agencies.
Sources: en.wikipedia.org
It is a synthetic peptide of fifteen amino acids whose sequence matches a fragment of a protein found in human gastric juice. It is studied mainly in laboratory and animal research rather than as an approved medicine.
The letters abbreviate body protection compound, the name given to the parent protein isolated from gastric juice. The number is an identifier attached to the specific fragment, not a dose or a description of a chemical property.
The sequence corresponds to a segment of an endogenous gastric protein, but the isolated fifteen-amino-acid peptide is a synthetic construct. Whether the free fragment circulates in humans at measurable levels is not clearly established in the published literature.
The standard approach is reverse-phase high-performance liquid chromatography, reported as a percentage of total peak area. Because that figure alone says little about the nature of the impurities, the accompanying chromatogram is normally the more useful document for judging a batch.